$1.01
0.97% yesterday
Nasdaq, Apr 17, 10:00 pm CET
ISIN
US0547544033
Symbol
AYTU

Aytu BioScience Inc Stock price

$1.01
-0.22 17.88% 1M
-1.28 55.89% 6M
-0.69 40.58% YTD
-1.86 64.85% 1Y
-17.26 94.47% 3Y
-274.99 99.63% 5Y
-2,337,406.99 100.00% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.01 0.97%
ISIN
US0547544033
Symbol
AYTU

Key metrics

Market capitalization $6.23m
Enterprise Value $2.97m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 5.60
EV/Sales (TTM) EV/Sales 0.04
P/S ratio (TTM) P/S ratio 0.09
P/B ratio (TTM) P/B ratio 0.20
Revenue growth (TTM) Revenue growth -30.19%
Revenue (TTM) Revenue $68.76m
EBIT (operating result TTM) EBIT $-4.27m
Free Cash Flow (TTM) Free Cash Flow $530.00k
Cash position $20.40m
EPS (TTM) EPS $-1.45
P/E forward 1.40
P/S forward 0.09
EV/Sales forward 0.04
Short interest 2.38%
Show more

Is Aytu BioScience Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Aytu BioScience Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aytu BioScience Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aytu BioScience Inc:

Buy
100%

Financial data from Aytu BioScience Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
69 69
30% 30%
100%
- Direct Costs 27 27
35% 35%
39%
42 42
27% 27%
61%
- Selling and Administrative Expenses 36 36
29% 29%
53%
- Research and Development Expense 2.61 2.61
7% 7%
4%
2.87 2.87
14% 14%
4%
- Depreciation and Amortization 7.14 7.14
20% 20%
10%
EBIT (Operating Income) EBIT -4.27 -4.27
24% 24%
-6%
Net Profit -5.24 -5.24
71% 71%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about Aytu BioScience Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aytu BioScience Inc Stock News

Neutral
Seeking Alpha
2 months ago
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good day, everyone, and welcome to the Aytu BioPharma Fiscal 2025 Q2 Earnings Call. At ...
Neutral
Accesswire
2 months ago
Net income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023 $20.4 million cash balance at December 31, 2024 Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / F...
Neutral
Accesswire
2 months ago
DENVER, CO / ACCESS Newswire / February 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its second quarter of fiscal 2025, after the market close on Wednesday, February 12, 2025. The Company has scheduled a conference call and webcast that same da...
More Aytu BioScience Inc News

Company Profile

Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Head office United States
CEO John Donofrio
Employees 102
Founded 2002
Website www.aytubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today